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Abstract
Background: Middle East Respiratory Syndrome coronavirus (MERS-CoV) is a viral respiratory disease. Most people
infected with MERS-CoV develop severe acute respiratory illness. It was first reported in Saudi Arabia in 2012 and
has since spread to several other countries. We report the clinical course of MERS-CoV infection in a pregnant
woman who acquired the infection during the last trimester.
Case presentation: The patient is a 33-year-old female working as a critical care nurse. She was 32 weeks pregnant
when she presented with respiratory symptoms after direct contact with a MERS-COV patient. Although the patient
was in respiratory failure, necessitated mechanical ventilation, and intensive care (ICU) admission, a healthy infant
was delivered. The mother recovered. To the best of our knowledge, this is the first reported case of a laboratory-
confirmed Middle East Respiratory Syndrome Coronavirus in a pregnant woman.
Conclusions: Middle East Respiratory Syndrome coronavirus (MERS-CoV) known to cause severe acute respiratory
illness associated with a high risk of mortality Various factors may have contributed to the successful outcome of
this patient such as young age, presentation during the last stages of pregnancy, and possible differences in
immune response.
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Background
Middle East Respiratory Syndrome coronavirus (MERS-
CoV) is a novel coronavirus known to cause severe acute
respiratory illness associated with a high risk of mortal-
ity. As of August 17 2015, 1432 laboratory-confirmed
cases of infection with MERS-CoV, including at least
507 deaths, have been confirmed worldwide [1]. In preg-
nant women, the risk of viral pneumonia is significantly
higher than for the rest of the population according to
data collected from the previous 1957–1958 pandemics,
and the H1N1 influenza pandemic of 2009 [2, 3].
Pregnant women with severe acute respiratory syndrome
(SARS) appear to have a worse clinical outcome and
a higher mortality rate compared to non-gravid
women [4, 5]. Rates of maternal mortality, stillbirth,
spontaneous abortion, and preterm delivery have all
been elevated in viral pneumonia such as influenza-A,
virus subtype H1N1, and SARS. While there are no
clinical or serologic reports suggesting transmission of
SARS coronavirus to the fetus, vertical transmission
has been reported for H1N1 and Respiratory Syncytial
Virus (RSV) [4, 6]. Data on the effects of MERS-CoV
on pregnancy are limited; two cases of MERS-CoV in
pregnancy have been reported to this day. The first
report involved a stillbirth at 5 months of gestation
in a woman with MERS-CoV infection in Jordan [7].
The other involved a woman in the United Arab
Emirates with MERS-CoV infection during the 3rd
trimester who died after giving birth to a healthy
baby with no evidence of MERS-CoV infection [8].
We report the clinical course of MERS-CoV infection
in a pregnant woman who acquired the infection dur-
ing the last trimester of pregnancy during a large
hospital outbreak.
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Case presentation
The patient was a 33-year-old female working as a crit-
ical care nurse, with a prior history of hypothyroidism
and primary infertility. She had undergone successful in
vitro fertilization prior to presentation. She had been ex-
posed to a patient with a respiratory illness, later identi-
fied as MERS-CoV infection, and was using standard
contact and droplet precautions while under her care.
Three days after exposure, she began to exhibit a dry
cough and fever prompting her to visit a family medical
clinic, where she was prescribed antipyretics. Over the
following week, her symptoms gradually worsened, with
increasing cough, shortness of breath, and persistent
fever prompting her to come to the emergency depart-
ment. She was hospitalized and diagnosed with pneumo-
nia. Two nasopharyngeal swabs were taken, and the
patient was admitted to a negatively pressurized room
with contact, droplet, and airborne transmission precau-
tion protocols in place.
On admission, her highest recorded temperature was
39.2 °C, and her oxygen saturation was maintained via
room air (97 − 99 %). Chest radiography showed diffuse
bilateral lower lobe infiltrates (Fig. 1). Other laboratory
findings included a leukocyte count of 6600/mm3
comprised of 81 % polymorphonuclear cells, 13 %
lymphocytes, and 5 % monocytes; a platelet count of
127,000/mm3; alanine aminotransferase concentration
of 254 U/L; and aspartate aminotransferase concentra-
tion of 258 U/L. The patient displayed normal renal
function. A fetal ultrasound, performed upon admission,
demonstrated a live intrauterine fetus of approximately
31 weeks of gestational age, and a posteriorly located
placenta. MERS-CoV RNA was not detected in a nasal
swab taken at that time.
Treatment with intravenous imipenem, vancomycin,
azithromycin and oseltamivir were initiated. Despite
antibiotic therapy, the patient became increasingly
dyspneic over the following 3 days. Arterial blood gas
analysis showed pH 7.34, PaCO2 36 mmHg, and PaO2
73 mmHg while on room air. She also exhibited radio-
graphic evidence of progressive pulmonary infiltrates.
Five hours later, the patient developed respiratory failure.
She required mechanical ventilation, and dexamethasone
was administered twice as prophylaxis for the fetus. A
cesarean section was performed at 32 weeks of gestation,
and a healthy 1.79 kg preterm male infant was delivered
without complications. Following an uneventful delivery,
the patient was transferred to the intensive care unit
(ICU). Her oxygen requirement increased to 100 %,
chest radiography revealed bilateral consolidation, and
her condition progressed to acute respiratory distress
syndrome (ARDS). Nine days after the initial onset of in-
fection, polymerase chain reaction (PCR) analysis, using
real-time reverse transcription PCR (rRT-PCR) targeting
genes E and 1a open reading frame, of tracheal aspirate
confirmed the presence of MERS-COV infection [9].
Combination therapy with IFN-alpha-2b and ribavirin
were initiated, as was methylprednisolone for ARDS.
Subsequent septic screening samples including urine,
blood, and sputum cultures were all negative for bacter-
ial super infections.
Over the next 4 days, the patient began to improve.
Chest radiography showed interval improvement, her
fever resolved, her oxygen requirement decreased. Re-
peated blood tests showed normal leukocyte and platelet
counts, and liver function test came back to normal. Five
days later, the patient was weaned from mechanical
ventilation, and transferred to the medical ward. She
continued to recover uneventfully, and was discharged
28 days after hospital admission.
All health care workers taking care of her were asymp-
tomatic with negative nasopharyngeal swab for MERS-
Cov PCR, except for a 50-year old female nurse, with no
comorbidities, from the obstetrics and gynecology ward.
The patient was under her care prior to being trans-
ferred to the ICU with progressive and severe pneumo-
nia. She had unprotected exposure for 2 min with 50 cm
distance separation between her and the patient. The
nurse clearly mentioned that the patient was coughing
in her direction during that transient exposure. She was
later admitted for 3 days with self-limiting MERS-Cov
pneumonia, based on positive MERS-Cov PCR nasopha-
ryngeal swab and bilateral lung infiltrate. She was dis-
charged and sent home in a stable condition.
The male infant in the case reported herein was deliv-
ered by emergency cesarean under contact, droplet, and
airborne transmission precautions. He was kept in the
neonatal unit for observation, and was fed artificial
Fig. 1 Chest Radiography (postero-anterior view) showing
bilateral infiltration
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formula in replacement of breast milk. Repeated naso-
pharyngeal swabs PCR analyses showed a consistently
negative result for MERS-CoV. All healthcare workers in
contact with the infant during his delivery, and subse-
quent care, have remained asymptomatic.
Discussion
The severity of viral pneumonia in pregnancy is evi-
dently related to physiological and immunological
changes that result in a shift from cell-mediated to
humoral-mediated immunity [10]. Different outcomes in
pregnancy have been reported in association with differ-
ent viral respiratory illnesses, including pandemic
influenza, H1N1, and SARS [4]. Among the 12 gravid
women who presented with SARS in Hong Kong, be-
tween February 1st and July 31st in 2003, 50 % required
ICU admission, 33 % required mechanical ventilation,
57 % who presented during the first trimester had spon-
taneous miscarriages, and 80 % of those presenting late
in pregnancy underwent preterm deliveries. Over 80 %
of the women gave birth via emergency cesarean second-
ary to failure at maintain adequate blood oxygen satur-
ation, despite being on 100 % oxygen [4].
In the present report, we have described a serious case
of MERS-CoV during the 3rd trimester of pregnancy, re-
quiring mechanical ventilation. This case differs from
those reported previously that were associated with still-
birth in the 2nd trimester, during the MERS-CoV out-
break that occurred in Jordan from February through
April in 2012 [8]. Our patient had an uneventful peri-
natal course, and a successful outcome. Various factors
may have contributed to this, including the timing of
MERS-CoV exposure during pregnancy, her young age,
the use of steroids, and potential differences in immune
responses. While combination therapy with ribavirin and
interferon was administered, it is unlikely that either
contributed to the successful outcome; because both
were given after delivery, as MERS-COV was not con-
firmed until later in the course of her illness.
There is limited information available on pregnancy,
during antenatal, birth, or postnatal period, and MERS-
CoV infection. Antiviral therapy has not yet been ap-
proved for the treatment of gravid patients with MERS-
CoV infection. A retrospective cohort study in patients
with severe MERS-CoV infection showed that the com-
bined administration of ribavirin and IFN-alpha-2a
seemed to significantly improve survival rate at day 14
but not day 28 [11]. However, other retrospective studies
have failed to show any improvement in the mortality
rate following this combination therapy [12]. During the
SARS outbreak of 2003, ribavirin was used in pregnant
women with the most severe forms of the illness. How-
ever, ribavirin therapy increases the risk of teratogenic
effects in newborns [13]. Therefore, the use of this drug
is not recommended during pregnancy or lactation.
Drug treatment of MERS-CoV in pregnancy requires
further investigation in the clinical setting.
This report provides an initial view of the outcome as-
sociated with pregnancy-related MERS CoV infection.
Further data on larger numbers of gravid women in-
fected with MERS-CoV will facilitate a better under-
standing of the impact of MERS-CoV infection on
perinatal outcome.
Conclusion
Middle East Respiratory Syndrome coronavirus (MERS-
CoV) known to cause severe acute respiratory illness as-
sociated with a high risk of mortality Various factors
may have contributed to the successful outcome of our
patient infected with MERS-COV, including young age,
presentation in late trimester, and differences in immune
responses.
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